Race for Lead Plaintiff in aTyr Securities Case Nears Dec. 8 Deadline After Phase 3 Trial Failure

Overview

• aTyr disclosed on Sept. 15 that the Phase 3 EFZO-FIT study failed its primary endpoint measuring change from baseline in mean daily oral corticosteroid dose at week 48.
• Shares fell from $6.03 on Sept. 12 to $1.02 on Sept. 15, an 83.2% single-day decline tied to the trial results.
• Complaints claim executives overstated efzofitimod’s efficacy, including its ability to enable complete steroid tapering, and misled investors about the study’s prospects.
• Hagens Berman, the Law Offices of Howard G. Smith, Levi & Korsinsky, Rosen Law Firm, and Bragar Eagel & Squire are seeking lead-plaintiff roles with differing proposed class periods, including Nov. 7, 2024–Sept. 12, 2025 and Jan. 16, 2025–Sept. 12, 2025.
• The case is filed in the Southern District of California, aTyr has said it will consult the FDA on next steps for efzofitimod, and no class has been certified.